GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomics Biopharma Ltd (ASX:BBM) » Definitions » Price-to-Tangible-Book

Biomics Biopharma (ASX:BBM) Price-to-Tangible-Book : (As of Jun. 13, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Biomics Biopharma Price-to-Tangible-Book?

As of today (2024-06-13), Biomics Biopharma's share price is A$0.00. Biomics Biopharma's Tangible Book per Share of . 20 for the quarter that ended in . 20 was A$0.00. Hence, Biomics Biopharma's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Biomics Biopharma's Price-to-Tangible-Book or its related term are showing as below:

ASX:BBM's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.8
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Biomics Biopharma's share price is A$0.00. Biomics Biopharma's Book Value per Sharefor the quarter that ended in . 20 was A$0.00. Hence, Biomics Biopharma's P/B Ratio of today is .


Biomics Biopharma Price-to-Tangible-Book Historical Data

The historical data trend for Biomics Biopharma's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomics Biopharma Price-to-Tangible-Book Chart

Biomics Biopharma Annual Data
Trend
Price-to-Tangible-Book

Biomics Biopharma Semi-Annual Data
Price-to-Tangible-Book

Competitive Comparison of Biomics Biopharma's Price-to-Tangible-Book

For the Biotechnology subindustry, Biomics Biopharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomics Biopharma's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomics Biopharma's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Biomics Biopharma's Price-to-Tangible-Book falls into.



Biomics Biopharma Price-to-Tangible-Book Calculation

Biomics Biopharma's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: . 20 )
=0.00/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Biomics Biopharma Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Biomics Biopharma's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomics Biopharma (ASX:BBM) Business Description

Traded in Other Exchanges
N/A
Address
1 Macquarie Place, Level 36, Gateway Tower, Sydney, NSW, AUS, 2000
Biomics Biopharma Ltd is a near-clinical-stage biopharmaceutical company in developing and commercialising double stranded ribonucleic acid (dsRNA) based innovative products for unmet medical needs.

Biomics Biopharma (ASX:BBM) Headlines

No Headlines